| Members |
targetComponentId |
| Myelosclerosis with myeloid metaplasia |
Primary myelofibrosis |
| Myocardial infarction clinical management plan |
Myocardial infarction clinical management plan (record artifact) |
| Myocarditis NOS |
Myocarditis |
| Myocarditis NOS |
Myocarditis |
| Myoma, no International Classification of Diseases for Oncology subtype |
Myoma |
| Myometrial hyperplasia |
Hyperplasia of myometrium (disorder) |
| Myotenontoplasty |
Myotenoplasty |
| Myotenoplasty of hand |
Myotenoplasty |
| Myotension technique |
Muscle energy technique (procedure) |
| Myovirus group |
Family Myoviridae (organism) |
| Myringoplasty NEC |
Myringoplasty (procedure) |
| Myringoplasty NEC |
Myringoplasty (procedure) |
| Myringotomy including aspiration with general anesthesia |
Myringotomy and drainage of middle ear (procedure) |
| N-b-bis (2-chloroethyl)-2-naphthylamine |
Chlornaphazine (substance) |
| N0 category |
American Joint Committee on Cancer cN0 (qualifier value) |
| N1: Metastasis in 1-3 lymph nodes |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in 1-6 perigastric lymph nodes |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in a single ipsilateral lymph node, < 3 cm in greatest dimension |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in a single lymph node |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in a single lymph node, < 2 cm in greatest dimension |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in a single lymph node, <= 2 cm in greatest dimension |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, including intrapulmonary nodes involved by direct extension of the primary tumor |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in perirectal lymph node or nodes |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis in regional lymph node or nodes |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis to movable ipsilateral axillary lymph node(s) |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Metastasis with a lymph node mass less than 2 cm in greatest dimension and 5 or fewer positive nodes, none larger than 2 cm in greatest dimension |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Pelvic or inguinal lymph node metastasis |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Regional lymph node metastasis |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1: Unilateral metastasis in lymph node(s) > 6 cm in greatest dimension, above supraclavicular fossa |
American Joint Committee on Cancer cN1 (qualifier value) |
| N1a: 1-3 nodes involved |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Metastasis in ipsilateral cervical lymph node(s) |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Metastasis in single regional lymph node |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Only micrometastasis, none > 0.2 cm in greatest dimension |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1b: 4-7 nodes involved |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis in bilateral, midline, or contralateral cervical or mediastinal lymph node(s) |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis in multiple regional lymph nodes |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis to lymph node(s), any > 0.2 cm in greatest dimension |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1c: >7 nodes involved |
American Joint Committee on Cancer cN1c (qualifier value) |
| N2 category |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Bilateral metastasis in lymph node(s) > 6 cm in greatest dimension, above supraclavicular fossa |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis in 4 or more lymph nodes |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis in 7-15 perigastric lymph nodes |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis in a single ipsilat lymph node >3cm but <6cm in greatest dimension; or in multiple ipsilat lymph nodes, none >6cm in greatest dimension; or in bilat or contralat lymph nodes, none >6cm in greatest dimension |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis in a single lymph node, > 2 cm but <= 5 cm in greatest dimension, or multiple lymph nodes, none > 5 cm in greatest dimension |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis in more than one regional lymph node |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis to ipsilateral axillary lymph node(s) fixed to one another or to other structures |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis to unilateral internal iliac and/or inguinal lymph node(s) |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2: Metastasis with a lymph node mass >2 cm but <= 5 cm in greatest dimension, or more than 5 nodes positive, none > 5 cm; or evidence of extranodal extension of tumor |
American Joint Committee on Cancer cN2 (qualifier value) |
| N2a: Metastasis in a single ipsilateral lymph node, > 3 cm but < 6 cm in greatest dimension |
American Joint Committee on Cancer cN2a (qualifier value) |
| N2b: Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension |
American Joint Committee on Cancer cN2b (qualifier value) |
| N2c: Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension |
American Joint Committee on Cancer cN2c (qualifier value) |
| N3 category |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3: Metastasis in >15 perigastric lymph nodes |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3: Metastasis in a lymph node > 5 cm in greatest dimension |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3: Metastasis in a lymph node > 6 cm in greatest dimension |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node(s) |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3: Metastasis in lymph node(s) |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3: Metastasis to ipsilateral internal mammary lymph node(s) |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3: Metastasis with a lymph node mass > 5 cm in greatest dimension |
American Joint Committee on Cancer cN3 (qualifier value) |
| N3a: > 6 cm in dimension |
American Joint Committee on Cancer cN3a (qualifier value) |
| N3b: extension to supraclavicular fossa |
American Joint Committee on Cancer cN3b (qualifier value) |
| NAD(P)H dehydrogenase (FMN) |
NAD(P)H dehydrogenase (quinone) |
| NX category |
American Joint Committee on Cancer cNX (qualifier value) |
| Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
| Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
| Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
| Nabumetone 500mg dispersible tablet |
Nabumetone 2.5 mg/mL oral solution |
| Nail dystrophy resulting from poisonous chemical |
Nail dystrophy caused by chemical |
| Nail flap |
Flap (substance) |
| Nairobi sheep disease serogroup |
Nairobi sheep disease virus |
| Nape of neck flap |
Flap (substance) |
| Naphazoline hydrochloride + polyvinyl alcohol + zinc sulfate 0.02%wv/0.25%wv/0.25%wv drops |
Product containing only naphazoline and polyvinyl alcohol and zinc sulfate (medicinal product) |
| Naproxen 200mg/pseudoephedrine 120mg m/r tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen 200mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen 500mg m/r tablet |
Product containing precisely naproxen 500 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 220mg/pseudoephedrine 120mg m/r tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen sodium 220mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen sodium 375mg gastro-resistant oral tablet |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 375mg m/r tablet |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 500mg gastro-resistant oral tablet |
Naproxen only product in oral dose form |
| Naproxen sodium 500mg m/r tablet |
Naproxen only product in oral dose form |
| Narrow open angle |
Narrow angle (finding) |
| Nasal cavity and ethmoid sinus TNM finding |
American Joint Committee on Cancer allowable value |
| Nasal diagnostic laryngoscopy |
Nasal laryngoscopy |
| Nasal flap |
Flap (substance) |
| Nasal sinus operations NOS |
Operation on accessory sinus |
| Nasal sinus operations NOS |
Operation on accessory sinus |
| Nasal sinusectomy - other |
Accessory sinus excision |
| Nasal sinusectomy - other |
Accessory sinus excision |
| Nasal sinusotomy - other |
Operation on accessory sinus |
| Nasal sinusotomy - other |
Operation on accessory sinus |
| Nasalis flap |
Flap (substance) |
| Nasolabial flap |
Flap (substance) |
| Nasopharyngoscopy: [diagnostic NEC] or [NEC] |
Nasopharyngoscopy |
| Nasopharynx TNM finding |
American Joint Committee on Cancer allowable value |
| National gov't. officer NOS |
National government officer (occupation) |
| National government general administrator NOS |
Government administrator |
| National government general administrator NOS |
Government administrator |
| National government officer NOS |
National government officer (occupation) |
| Natural scientist NOS |
Natural scientist |
FHIR